IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS

被引：0
|
作者：
Kovtun, Y. [1 ]
Jones, G. [1 ]
Harvey, L. [1 ]
Rui, L. [1 ]
Audette, C. [1 ]
Liu, F. [1 ]
Bai, C. [1 ]
Wilhelm, A. [1 ]
Yoder, N. C. [1 ]
Adams, S. [1 ]
Goldmacher, V. S. [1 ]
Chari, R. [1 ]
Chittenden, T. [1 ]
机构：
[1] ImmunoGen Inc, Waltham, MA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB582
引用
收藏
页码：222 / 222
页数：1
相关论文
共 50 条
  • [1] IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
    Adams, Sharlene
    Wilhelm, Alan
    Harvey, Lauren
    Bai, Chen
    Yoder, Nicholas
    Kovtun, Yelena
    Chittenden, Thomas
    Pinkas, Jan
    BLOOD, 2016, 128 (22)
  • [2] A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
    Kovtun, Yelena
    Jones, Gregory E.
    Adams, Sharlene
    Harvey, Lauren
    Audette, Charlene A.
    Wilhelm, Alan
    Bai, Chen
    Rui, Lingyun
    Laleau, Rassol
    Liu, Fenghua
    Ab, Olga
    Setiady, Yulius
    Yoder, Nicholas C.
    Goldmacher, Victor S.
    Chari, Ravi V. J.
    Pinkas, Jan
    Chittenden, Thomas
    BLOOD ADVANCES, 2018, 2 (08) : 848 - 858
  • [3] Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Martinelli, Giovanni
    Todisco, Elisabetta
    Lane, Andrew A.
    Acuna-Cruz, Evelyn
    Deconinck, Eric
    Wang, Eunice S.
    Sweet, Kendra
    Rizzieri, David A.
    Marconi, Giovanni
    Mazzarella, Luca
    DeAngelo, Daniel J.
    Montesinos, Pau
    Gigli, Federica
    Erba, Harry P.
    Konopleva, Marina
    Kantarjian, Hagop
    Walter, Roland B.
    Aribi, Ahmed
    Lebon, Delphine
    Levy, Moshe Y.
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Daver, Naval
    BLOOD, 2021, 138
  • [4] A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells
    Kovtun, Yelena
    Jones, Gregory
    Audette, Charlene
    Harvey, Lauren
    Gerard, Baudouin
    Wilhelm, Alan
    Bai, Chen
    Adams, Sharlene
    Goldmacher, Victor S.
    Chari, Ravi
    Chittenden, Thomas
    BLOOD, 2016, 128 (22)
  • [5] Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models
    Kuruvilla, Vinitha Mary
    Zhang, Qi
    Daver, Naval
    Watkins, Krystal
    Sloss, Callum M.
    Zweidler-McKay, Patrick A.
    Romanelli, Angela
    Konopleva, Marina
    BLOOD, 2020, 136
  • [6] Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models
    Zhang, Qi
    Cai, Tianyu
    Han, Lina
    Kuruvilla, Vinitha Mary
    Adams, Sharlene
    Callum, Sloss M.
    Harutyunyan, Karine
    Lane, Andrew A.
    Kovtun, Yelena
    Daver, Naval G.
    Pemmaraju, Naveen
    Mckay, Patrick Zweider
    Konopleva, Marina Y.
    BLOOD, 2018, 132
  • [7] Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
    Daver, Naval G.
    Montesinos, Pau
    Deangelo, Daniel J.
    Wang, Eunice S.
    Papadantonakis, Nikolaos
    Todisco, Elisabetta
    Sweet, Kendra L.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Torres-Minana, Laura
    Thompson, James E.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Watkins, Krystal
    Bedse, Gaurav
    Du, Yining
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    LANCET ONCOLOGY, 2024, 25 (03): : 388 - 399
  • [8] A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Marconi, Giovanni
    Todisco, Elisabetta
    Montesinos, Pau
    Lane, Andrew A.
    Sweet, Kendra
    Wang, Eunice S.
    Deconinck, Eric
    Rizzieri, David A.
    Walter, Roland B.
    Aribi, Ahmed
    Lebon, Delphine
    Levy, Moshe Y.
    Mazzarella, Luca
    Martinelli, Giovanni
    Gigli, Federica
    Erba, Harry P.
    Acuna-Cruz, Evelyn
    Konopleva, Marina
    Kantarjian, Hagop
    Sloss, Callum M.
    Wang, Jiuzhou
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    DeAngelo, Daniel J.
    Daver, Naval
    BLOOD, 2021, 138
  • [9] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Martinelli, Giovanni
    Todisco, Elisabetta
    Lane, Andrew A.
    Acuna-Cruz, Evelyn
    Deconinck, Eric
    Wang, Eunice S.
    Sweet, Kendra L.
    Rizzieri, David A.
    Mazzarella, Luca
    DeAngelo, Daniel J.
    Montesinos, Pau
    Tarella, Corrado
    Erba, Harry P.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Daver, Naval
    BLOOD, 2020, 136
  • [10] Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
    Cole, Frances M.
    Laszlo, George S.
    Lunn-Halbert, Margaret C.
    Kehret, Allie R.
    Zweidler-McKay, Patrick A.
    Rodriguez-Arboli, Eduardo
    Wu, David
    Nyberg, Kyle E.
    Li, Junyang
    Lim, Sheryl Y. T.
    Lakshmikanthan, Sribalaji
    Walter, Roland B.
    BLOOD, 2024, 144 : 2751 - 2751
12345